COOPER COMPANIES, INC.
Ticker: COOHealthcareMedical InstrumentsS&P 500The business
Cooper Companies, Inc. (NASDAQ: COO) is a leading global medical device company headquartered in San Ramon, California, with operations spanning over 130 countries and positively impacting more than fifty million lives annually. The company operates through two primary business segments: CooperVision and CooperSurgical, which together provide comprehensive solutions in vision care, fertility, and women's health.
CooperVision manufactures and markets a broad range of contact lenses globally, including single-use, two-week, and monthly modalities featuring advanced silicone hydrogel materials and optics. The segment addresses vision challenges such as astigmatism, presbyopia, and myopia through spherical, toric, and multifocal lens designs. CooperVision's portfolio includes premium brands such as Biofinity, MyDay, and clariti 1 day, alongside specialty products including orthokeratology and scleral lenses. The company holds a significant competitive advantage through MiSight 1 day, the first and only FDA-approved contact lens for slowing myopia progression in children aged eight to twelve, with approvals also obtained in China and Japan. Major manufacturing and distribution facilities operate in Belgium, Costa Rica, Hungary, Puerto Rico, the United Kingdom, and the United States.
CooperSurgical offers over six hundred products and services focused on fertility and women's health, categorized into office and surgical products used by obstetricians and gynecologists, and fertility products and services utilized in fertility clinics. The segment's portfolio encompasses surgical instruments, contraception solutions including the hormone-free Paragard intrauterine device, cord blood and cord tissue cryostorage services, and comprehensive fertility support including donor gametes, cryopreservation, and genomic testing services. CooperSurgical maintains major facilities in Costa Rica, the Netherlands, the United Kingdom, and the United States.
The company employs approximately five hundred people in research and development across both segments. Cooper competes on the basis of product quality, technological differentiation, pricing, service levels, and manufacturing efficiency. The company maintains ISO 13485 certification and CE marks for its products, with additional ISO 15189 certification for genomics laboratories. Cooper's website is www.coopercos.com.
- Sector
- Healthcare
- Industry
- Medical Instruments
- HQ
- SAN RAMON, CA
- FY end
- 10-31
- CIK
- 711404
- SIC
- 3851
Ownership
Who holds COOPER COMPANIES, INC. — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.02% | $443.93M |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 0.02% | $362.63M |
| VANGUARD SMALL-CAP INDEX FUND VB · VANGUARD INDEX FUNDS | 0.17% | $320.84M |
| T. Rowe Price Mid-Cap Growth Fund, Inc. RPMGX · T. ROWE PRICE MID-CAP GROWTH FUND, INC. | 1.21% | $278.50M |
| VANGUARD SMALL-CAP VALUE INDEX FUND VBR · VANGUARD INDEX FUNDS | 0.30% | $203.27M |
Superinvestors in COOPER COMPANIES, INC.
Share of each manager's reported 13F portfolio.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of COOPER COMPANIES, INC.'s financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free